332109-91-8

Basic information

• Product Name: 2-chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoyl chloride
• Synonyms: 2-chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoyl chloride
• CAS NO: 332109-91-8
• Molecular Weight: 255.103
• Mol File: 332109-91-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoyl chloride(332109-91-8)
• EPA Substance Registry System: 2-chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoyl chloride(332109-91-8)

Safety Data

• Hazardous Substances Data: 332109-91-8(Hazardous Substances Data)

Upstream product

• 220436-05-5 2-Chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoic Acid 
• 185312-82-7 4-bromo-2-chlorobenzoic acid methyl ester 
• 220436-03-3 2-Chloro-4-(1H-pyrazol-3-yl)-benzoic acid methyl ester 
• 220436-02-2 2-chloro-4-(3-dimethylaminopropyn-1-yl)-benzoic acid methyl ester 
• 220436-04-4 2-chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoic acid methyl ester 

Downstream Products

• 220436-06-6 [2-Chloro-4-(1-methyl-1H-pyrazol-3-yl)-phenyl]-(5H,11H-pyrrolo[2,1-c]-[1,4]benzodiazepine-10-yl)-methanone 
• 220436-07-7 [2-Chloro-4-(1-methyl-1H-pyrazol-3-yl)-phenyl]-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone 

Relevant articles and documents

Pyridobenzodiazepines: A novel class of orally active, vasopressin V 2 receptor selective agonists

Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.

TRICYCLIC VASOPRESSIN AGONISTS

The present invention provides compounds of general formula (I): wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilising these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.